Literature DB >> 2045309

On using the linear-quadratic model in daily clinical practice.

R J Yaes1, P Patel, Y Maruyama.   

Abstract

To facilitate its use in the clinic, Barendsen's formulation of the Linear-Quadratic (LQ) model is modified by expressing isoeffect doses in terms of the "Standard Effective Dose," Ds, the isoeffective dose for the "standard" fractionation schedule of 2 Gy fractions given once per day, 5 days per week. For any arbitrary fractionation schedule, where total dose D is given in N fractions of size d in a total time T, the corresponding "Standard Effective Dose," Ds, will be proportional to the total dose D and the proportionality constant will be called the "Standard Relative Effectiveness," SRE, to distinguish it from Barendsen's "Relative Effectiveness," RE. Thus, Ds = SRE.D. The constant SRE depends on the parameters of the fractionation schedule, and on the tumor or normal tissue being irradiated. For the "simple" LQ model with no time dependence, which is applicable to late reacting tissue, SRE = [(d + delta)/(2 + delta)], where d is the fraction size and delta = alpha/beta is the alpha/beta ratio for the tissue of interest, with both d and delta expressed in units of Gy. Application of this method to the Linear Quadratic model with a time dependence, the "LQ + time" model, and to low dose rate brachytherapy will be discussed. To clarify the method of calculation, and to demonstrate its simplicity, examples from the clinical literature will be used.

Entities:  

Mesh:

Year:  1991        PMID: 2045309     DOI: 10.1016/0360-3016(91)90249-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  13 in total

1.  Optimum inactivation dose and indices of radiation response based on the linear quadratic survival equation.

Authors:  B S Jacobson
Journal:  Radiat Environ Biophys       Date:  1993       Impact factor: 1.925

Review 2.  Current status of stereotactic body radiotherapy for lung cancer.

Authors:  Yasushi Nagata; Yukinori Matsuo; Kenji Takayama; Yoshiki Norihisa; Takashi Mizowaki; Michihide Mitsumori; Keiko Shibuya; Shinsuke Yano; Yuichiroh Narita; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2007-02-25       Impact factor: 3.402

Review 3.  Challenges in the treatment of early non-small cell lung cancer: what is the standard, what are the challenges and what is the future for radiotherapy?

Authors:  Almudena Cascales; Florent Martinetti; Deborah Belemsagha; Cecile Le Pechoux
Journal:  Transl Lung Cancer Res       Date:  2014-08

4.  Computed tomography appearances of local recurrence after stereotactic body radiation therapy for stage I non-small-cell lung carcinoma.

Authors:  Satoshi Kato; Atsushi Nambu; Hiroshi Onishi; Akitoshi Saito; Kengo Kuriyama; Takafumi Komiyama; Kan Marino; Tsutomu Araki
Journal:  Jpn J Radiol       Date:  2010-05-29       Impact factor: 2.374

5.  Proton Therapy for Primary Renal Cell Carcinoma: The First Nationwide Retrospective Study in Japan.

Authors:  Nobuyoshi Fukumitsu; Hitoshi Ishikawa; Takeshi Arimura; Hitoshi Wada; Tomoaki Okimoto; Yoshitaka Sato; Hiromitsu Iwata; Shosei Shimizu; Hideyuki Sakurai
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

6.  Helical tomotherapy provides efficacy similar to that of intensity-modulated radiation therapy with dosimetric benefits for endometrial carcinoma.

Authors:  Chen-Hsi Hsieh; Pei-Wei Shueng; Sheng-Mou Hsiao; Ming-Chow Wei; Wen-Yih Wu; Hsu-Dong Sun; Hui-Ju Tien; Li-Ying Wang; Yen-Ping Hsieh
Journal:  Onco Targets Ther       Date:  2012-10-01       Impact factor: 4.147

7.  Hypofractionated stereotactic radiotherapy for primary and secondary intrapulmonary tumors: first results of a phase I/II study.

Authors:  Antje Ernst-Stecken; Ulrike Lambrecht; Reinhold Mueller; Rolf Sauer; Gerhard Grabenbauer
Journal:  Strahlenther Onkol       Date:  2006-12       Impact factor: 3.621

8.  Spatio-Temporal Dynamics of Hypoxia during Radiotherapy.

Authors:  Harald Kempf; Marcus Bleicher; Michael Meyer-Hermann
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

9.  Intensity-modulated stereotactic body radiotherapy for stage I non-small cell lung cancer.

Authors:  Min-Jeong Kim; Seung-Gu Yeo; Eun Seok Kim; Chul Kee Min; Pyung Se An
Journal:  Oncol Lett       Date:  2012-12-18       Impact factor: 2.967

10.  Reactive oxygen species formation and bystander effects in gradient irradiation on human breast cancer cells.

Authors:  Dongqing Zhang; Tingyang Zhou; Feng He; Yi Rong; Shin Hee Lee; Shiyong Wu; Li Zuo
Journal:  Oncotarget       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.